Abstract | AIM: METHODS: RESULTS: In this study, we showed that treating the tumors with LY294002 could significantly inhibit carcinoma growth by 11.3%, 29.4% and 36.7%, after 5, 10 and 15 d, respectively, compared to the control group. Hematoxylin & eosin staining indicated that the rate of inhibition increased progressively (23.51% +/- 3.11%, 43.20% +/- 3.27% and 63.28% +/- 2.10% at 5, 10 and 15 d, respectively) along with apoptosis. The expression of MMP-2 was also downregulated (from 71.4% +/- 1.6% to 47.9% +/- 0.7%, 31.9% +/- 0.9% and 7.9% +/- 0.7%). The same effects were observed in MMP-9 protein expression (from 49.4% +/- 1.5% to 36.9% +/- 0.4%, 23.5% +/- 0.9% and 7.7% +/- 0.6%), the mean MVD (from 51.2% +/- 3.1% to 41.9% +/- 1.5%, 30.9% +/- 1.7% and 14.9% +/- 0.8%), and the expression of VEGF (from 47.2% +/- 3.1% to 25.9% +/- 0.5%, 18.6% +/- 1.2% and 5.1% +/- 0.9%) by immunohistochemical staining. CONCLUSION: The class I PI3K inhibitor LY294002 could inhibit the invasiveness of gastric cancer cells by downregulating the expression of MMP-2, MMP-9, and VEGF, and reducing MVD.
|
Authors | Chun-Gen Xing, Bao-Song Zhu, Xiao-Qing Fan, Hui-Hui Liu, Xun Hou, Kui Zhao, Zheng-Hong Qin |
Journal | World journal of gastroenterology
(World J Gastroenterol)
Vol. 15
Issue 40
Pg. 5044-52
(Oct 28 2009)
ISSN: 2219-2840 [Electronic] United States |
PMID | 19859997
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, CD34
- Chromones
- Enzyme Inhibitors
- Morpholines
- Phosphoinositide-3 Kinase Inhibitors
- Vascular Endothelial Growth Factor A
- 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
- Matrix Metalloproteinase 2
- Matrix Metalloproteinase 9
|
Topics |
- Animals
- Antigens, CD34
(biosynthesis)
- Apoptosis
- Chromones
(pharmacology)
- Enzyme Inhibitors
(pharmacology)
- Gene Expression Regulation, Neoplastic
- Humans
- Immunohistochemistry
(methods)
- Matrix Metalloproteinase 2
(biosynthesis)
- Matrix Metalloproteinase 9
(biosynthesis)
- Mice
- Mice, Nude
- Morpholines
(pharmacology)
- Neoplasm Transplantation
- Phosphoinositide-3 Kinase Inhibitors
- Stomach Neoplasms
(drug therapy, metabolism)
- Vascular Endothelial Growth Factor A
(metabolism)
|